Menu
Search
|

Menu

Close
X

Aratana Therapeutics Inc PETX.OQ (NASDAQ Stock Exchange Global Market)

6.43 USD
+0.07 (+1.10%)
As of 2:29 AM IST
chart
Previous Close 6.36
Open 6.40
Volume 63,567
3m Avg Volume 76,046
Today’s High 6.55
Today’s Low 6.29
52 Week High 7.28
52 Week Low 3.68
Shares Outstanding (mil) 48.62
Market Capitalization (mil) 309.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
31
FY17
26
FY16
39
FY15
1
EPS (USD)
FY18
-0.143
FY17
-1.179
FY16
-0.932
FY15
-2.444
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
28.86
Price to Sales (TTM)
vs sector
7.55
23.49
Price to Book (MRQ)
vs sector
2.82
3.93
Price to Cash Flow (TTM)
vs sector
--
20.30
Total Debt to Equity (MRQ)
vs sector
23.29
15.17
LT Debt to Equity (MRQ)
vs sector
2.45
11.36
Return on Investment (TTM)
vs sector
-18.89
12.65
Return on Equity (TTM)
vs sector
-21.46
14.38

EXECUTIVE LEADERSHIP

Wendy Yarno
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Steven St. Peter
President, Chief Executive Officer, Director, Since 2012
Salary: $467,500.00
Bonus: --
Craig Tooman
Chief Financial Officer, Treasurer, Since 2014
Salary: $350,000.00
Bonus: --
Brent Standridge
Chief Operating Officer, Since 2016
Salary: --
Bonus: --
Ernst Heinen
Chief Development Officer, Since 2014
Salary: $302,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11400 Tomahawk Creek Pkwy Ste 34
LEAWOOD   KS   66211-2730

Phone: +1913.3531000

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

SPONSORED STORIES